Sandeep Fin
-
Upload
sandeep-singh -
Category
Documents
-
view
225 -
download
0
Transcript of Sandeep Fin
-
7/31/2019 Sandeep Fin
1/23
1
International Funding used in Dr. Reddys Lab
Submitted in partial fulfillment of the requirements for
Post Graduate Diploma in Management (PGDM)
By
Sandeep SinghRoll no. 37
Section-A (Full Time)
Class of 2010
Bharatiya Vidya Bhavans
Usha & Lakshmi Mittal Institute of Management
Copernicus Lane, Kasturba Gandhi Marg
New Delhi
Jan 2012
-
7/31/2019 Sandeep Fin
2/23
2
Contents
1. Company Overview ................................................................................................................................... 4
2. International Fundings Used by the Organization:Annual Report2010-2011 ........................................ 6
a) ADR Share and other Foreign ownership: ........................................................................................... 6
b) Schedules .............................................................................................................................................. 7
1.a: Schedule 1: Share Capital ............................................................................................................... 7
1.a: Interpretation: .............................................................................................................................. 10
1.b: Schedule 2: Reserves and Surplus................................................................................................ 11
1.b: Interpretation: ............................................................................................................................. 13
1.c: Schedule 4: Unsecured Load ........................................................................................................ 14
1.c: Interpretation: .............................................................................................................................. 15
1.d: Schedule 13: Other Income and Schedule 16: Operating and other expenses ............................... 16
1:d Interpretation: .............................................................................................................................. 17
3. Conclusion from Annual Statement 2010-2011: .................................................................................... 17
4. Analysis Based on Quarterly Results: Quarter 2, 2011-12 ..................................................................... 17
a) Effect of Depreciation in Rupee on Profits: ........................................................................................ 17
5. News Track .............................................................................................................................................. 18
6. Ratio Analysis: ......................................................................................................................................... 21
-
7/31/2019 Sandeep Fin
3/23
3
Table of Contents
Table 1: Distribution of shareholding on the basis of ownership ........................................................................... 6Table 2: Distribution of Shareholding according to Shareholders' class ................................................................. 6
Table 3: Schedule 1 Share Capital .................................................................................................................................7
Table 4: Dr. Reddy's Employees ADR Stock Option Scheme 2007 ........................................................................... 8
Table 5: Category B Par Value Options 31March2010 ............................................................................................ 9
Table 6; Category Par Value Option Year ended 31March2011 ............................................................................ 10
Table 7 Schedule 2: Reserves and Surplus ............................................................................................................ 11
Table 8: Schedule 5 Unsecured Loans .................................................................................................................. 14
Table 9: Schedule 13 and 16: Operating Income and Operating & Other Expenses. ............................................. 16
Figures
Figure 1: CAGR ....................................................................................................................................................... 4
Figure 2: Revenue .................................................................................................................................................. 5
http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021022http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021022http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021204http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021204http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021205http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021205http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021205http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021204http://c/Users/new%20user/Desktop/International%20Finance%20Project.doc%23_Toc314021022 -
7/31/2019 Sandeep Fin
4/23
4
1. Company Overview
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is established in 1984, It is an integrated global
pharmaceutical company, committed to providing affordable and innovative medicines for
healthier lives. Through its three businesses - Pharmaceutical Services and Active
Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of
products and services including Active Pharmaceutical Ingredients (APIs), Custom
Pharmaceutical Services (CPS), generics, biosimilars, differentiated formulations and News
Chemical Entities (NCEs).
Dr. Reddys Laboratories Ltd. therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and paediatrics. Major markets includeIndia, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New
Zealand.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to
other less-regulated markets that had the advantage of not having to spend time and money on a
manufacturing plant that that would gain approval from a drug licensing body such as the U.S.
Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability
from these unregulated markets enabled the company to begin focusing on getting approval from
drug regulators for their formulations and bulk drug manufacturing plants in more-developed
economies. This allowed their movement into regulated markets such as the US and Europe.
Dr. Reddy Labs have seen a CAGR of 21% in last 10 years. On 31st march 2001 their revenue
was Rs, 10,975 million which is now raised to 74,693 on 31st march 2011. The Companys
consolidated revenues increased by 6% to Rs. 74,693 million (US$ 1.7 billion) in 2010-11.
Revenues from Global Generics increased by 10% while PSAI revenues decreased by 4%. In
Figure 1: CAGR
-
7/31/2019 Sandeep Fin
5/23
5
2010-11, Dr. Reddys share of revenue from
The international businesses stood at 81%. The remaining 19% came from India. North America
(US and Canada) contributed to 31% of total revenues in 2010-11, versus 30% last year. Europe
accounted for 21% of total sales in 2010-11, compared to 24% in 2009-10. Russia and other CIS
countries contributed to 15% of total revenues
.
India
19%
North America
31%Russi a and Other
CIS Countries
15%
Europe
21%
Row
14%
Revenue
India
North America
Russia and Other CIS
Countries
Europe
Row
Figure 2: Revenue
-
7/31/2019 Sandeep Fin
6/23
6
2. International Fundings Used by the Organization:Annual Report2010-2011
a) ADR Share and other Foreign ownership:
Table 1: Distribution of shareholding on the basis of
ownership
From the table 1 we can see that foreign holing comprises 46.27% of total ownership, out of
which 18.74% is in the form of ADR (American Depository Receipt) / Foreign Nationals.
Table 2: Distribution of Shareholding according to Shareholders' class
-
7/31/2019 Sandeep Fin
7/23
7
From table 2 Distribution of shareholding according to Shareholders class we can see that
DRL(Dr. Reddys Lab) has 1 shareholder a holding equtity shares underlying ADR and these are
the benefecialries owners outside India.
b) Schedules
1.a: Schedule 1: Share Capital
Table 3: Schedule 1 Share Capital
1. Subscribed and paid-up share capital includes:
(a) 111,732,202 (previous year: 111,732,202) equity shares of Rs. Rs. 5/- each fully paid-
up, allotted as bonus shares. Out of total, 34,974,400 shares were allotted by
capitalization of General Reserve and 76,757,802 equity shares allotted as bonus shares
by capitalization of the Securities Premium Account in earlier years.
(b) 1,052,248 (previous year: 1,052,248) equity shares of Rs. 5/- each allotted pursuant
to a scheme of amalgamation with Standard Equity Fund Limited without payments
being received in cash.
-
7/31/2019 Sandeep Fin
8/23
8
(c) 20,571,768 (previous year: 20,571,768) equity shares of Rs. 5/- each allotted and
82,800 (previous year: 82,800) equity shares of Rs. 5/- each extinguished pursuant to a
scheme of amalgamation with erstwhile Cheminor Drugs Limited (CDL) without
payments being received in cash.
(d) 40,750,000 (previous year: 40,750,000) equity shares of Rs. 5/- each allottedagainst American Depository Shares (ADS).
(e) 17,204,304 (previous year: 17,204,304) equity shares of Rs. 5/- each allotted
against Global Depository Receipts (GDR) that were converted into ADS during the
year ended 31 March 2002.
(f) 226,776 (previous year: 226,776) equity shares of Rs. 5/- each allotted to the erstwhile
members of American Remedies Limited (ARL) pursuant to a scheme of amalgamation
with ARL without payments being received in cash..
(g) 1,548,579 (previous year: 1,185,283) equity shares of Rs. 5/- each allotted to the
eligible employees of the Company and its subsidiaries on exercise of the vested stock
options in accordance with the terms of exercise under the Dr. Reddys Employees
Stock Option Plan, 2002. (Refer Note 9, Schedule 20).
(h) 190,634 (previous year: 146,583) equity shares of Rs. 5/- each allotted to the eligible
employees of the Company and its subsidiaries on exercise of the vested stock options in
accordance with the terms of exercise under the Dr. Reddys Employees Stock Option
Plan, 2007. (Refer Note 9, Schedule 20).
2. Represents 200 (previous year: 200) equity shares of Rs. 5/- each, amount paid-up Rs. 500/-(rounded off in millions in the Schedule above) forfeited due to nonpayment of allotment money.
3. 718,161 (previous year: 885,007) stock options are outstanding to be issued by the Company
on exercise of the vested stock options in accordance with the terms of exercise under the Dr.
Reddys Employees Stock Option Plan, 2002 and 124,559 (previous year: 112,390) stock
options are outstanding to be issued by the Company on exercise of the vested stock options
in accordance with the terms of exercise under the Dr. Reddys Employees ADR Stock
Option Pl an 2007 (Refer Note 9, Schedule 20).
Table 4: Dr. Reddy's Employees ADR Stock Option Scheme 2007
-
7/31/2019 Sandeep Fin
9/23
9
.
Money realized by exercise of options Rs. 9, 53,170. Total number of options in force 124,559
Table 5: Category B Par Value Options 31March2010
-
7/31/2019 Sandeep Fin
10/23
10
Table 6; Category Par Value Option Year ended 31March2011
1.a: Interpretation:
From Note 1 option d, e of table 3 Schedule 1 Share capital we can see that company had issued
GDR which had maturing date of 31st March 2002, they had converted those GDR into ADS
(American Depository Shares).
In accounting year 2010-11, 40, 750,000 (previous year: 40,750,000) equity shares of Rs. 5/-
each allotted against American Depository Shares.
Dr. Reddys Employees ADR Stock Option Plan 2007
The Company instituted the DRL 2007 Plan for all eligible employees in pursuance of the
special resolution approved by the shareholders in the Annual General. Meeting held on 27 July
2005. The DRL 2007 Plan came into effect on approval of the Board of Directors on 22 January
2007. The DRL 2007 Plan covers all employees of DRL and its subsidiaries and directors
(excluding promoter directors) of DRL and its subsidiaries (collectively, eligible employees).
Under the DRL. 2007 Plan, the Compensation Committee of the Board (the Compensation
Committee) shall administer the DRL 2007 Plan and grant stock options to eligible employees
of the Company and its subsidiaries.
The Compensation Committee shall determine the employees eligible for receiving the options,
the number of options to be granted, the exercise price, the vesting period and the exercise
period. The vesting period is determined for all options issued on the date of the grant. The
-
7/31/2019 Sandeep Fin
11/23
11
options issued under the DRL 2007 plan vest in periods ranging between one and four years and
generally have a maximum contractual term of five years.
During the current year, the Company under the DRL 2007 Plan has issued 58,660 options to
eligible employees. The vesting period for the options granted varies from 12 to 48 months. The
date of grant, number of options granted, exercise price fixed by the Committee for respectiveoptions and the market price of the shares of the Company on the date of grant is given below:
1.b: Schedule 2: Reserves and Surplus
Table 7 Schedule 2: Reserves and Surplus
(I): Schedule 20 Notes 1:
a) Foreign currency transactions and balances.
-
7/31/2019 Sandeep Fin
12/23
12
Foreign currency transactions are recorded using the exchange rates prevailing on the dates of
the respective transactions. Exchange differences arising on foreign currency transactions settled
during the year are recognised in the profit and loss account.
Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date, not
covered by forward exchange contracts, are translated at year-end rates. The resultant exchangedifferences are recognised in the profit and loss account. Non-monetary assets are recorded at the
rates prevailing on the date of the transaction.
Income and expenditure items at representative offices are translated at the respective monthly
average rates. Monetary assets at representative offices at the balance sheet date are translated
using the year-end rates. Non-monetary assets are recorded at the rates prevailing on the date of
the transaction.
Forward contracts are entered into to hedge the foreign currency risk of the underlying
outstanding at the balance sheet date. The premium or discount on all such contracts is amortizedas income or expense over the life of the contract. Any profit or loss arising on the cancellation
or renewal of forward contracts is recognised as income or expense for the period.
In relation to the forward contracts entered into to hedge the foreign currency risk of the
underlying outstanding at the balance sheet date, the exchange difference is calculated and
recorded in accordance with AS-11 (revised). The exchange difference on such a forward
exchange contract is calculated as the difference of the foreign currency amount of the contract
translated at the exchange rate at the reporting date, or the settlement date where the transaction
is settled during the reporting period and the corresponding foreign currency amount translated at
the later of the date of inception of the forward exchange contract and the last reporting date.Such exchange differences are recognized in the profit and loss account in the reporting period in
which the exchange rates change.
Exchange differences arising on a monetary item that, in substance, forms part of an enterprises
net investment in a non-integral foreign operation has been accumulated in a foreign currency
translation reserve in the enterprises financial statements until the disposal of the net investment,
at which time they should be recognised as income or as expense.
The financial statements of the foreign integral subsidiaries, representative offices and
collectively referred to as the foreign integral operations are translated into Indian rupees as
follows:
Revenue items, except depreciation are translated at the respective monthly average rates.
Depreciation is translated at the rates used for the translation of the values of the assets on
which depreciation is calculated.
-
7/31/2019 Sandeep Fin
13/23
-
7/31/2019 Sandeep Fin
14/23
-
7/31/2019 Sandeep Fin
15/23
15
packing credit loan that were taken from Standard Chartered Bank, The Bank of Nova Scotia,
BNP Paribas, ABN Amro Bank and HSBC carrying interest rates of LIBOR plus 4075 bps,
repayable on expiry of 6 months from the date of drawdown and Rupee packing credit from State
Bank of India carrying interest rate of 5% per annum.
3. Long-term foreign currency loan was guaranteed by the Company and certain subsidiaries ofthe Group. The loan carried an interest rate of EURIBOR plus 150 basis points. Effective 24
November 2006 the interest rate was changed to EURIBOR plus 70 basis points on euro portion
of the loan and LIBOR plus 70 basis points on dollar portion of the loan. During the year the
Group repaid the balance outstanding amount through three new short-term borrowings
aggregating to Rs. 5,972.
4. Bank overdraft is on the current accounts with Citibank, State Bank of India, HDFC and
HSBC bank carrying interest rates of 10.50%, 11.00%, 12.00% and 10.50% per annum,
respectively. (Bank overdraft in the previous year was on current accounts with Citibank, State
Bank of India and HDFC Bank carrying interest rates of 10.75%, 10.25% and 14.50% perannum, respectively).
5. Short-term loan taken by subsidiary from Citibank carrying interest rates of 1.95% 8% per
annum, from Bank of America carrying interest rate of 1.61% 1.79% per annum and from
Royal Bank of Scotland carrying interest rate of 5.38% per annum.
6. Loan from the State Bank of India taken by Aurigene Discovery Technologies Limited is
covered by way of Corporate Guarantee given by Parent Company. The loan carried an interest
rate of 11.75% per annum. This loan was fully repaid during the year.
7. Refer Note No 23 of Schedule 19. Amount repayable in 12 months is Rs. Nil.
1.c: Interpretation:
During the year 2010-2011 DRL has paid the Long term foreign currency loans of Rs.8, 899
Million. On the other hand company has raised its packing credit loans in which they have
borrowed money from various institutions like.
J.P.Morgan Chase. The Bank of Tokyo Mitsubishi UFJ LTD, BNP Paribas
-
7/31/2019 Sandeep Fin
16/23
16
HSBCOn which they are paying interest rates of LIBOR plus 5280 bps. Then they have taken fixed
interest rate loans from:
Credit Agricole Corporate & Investment Bank
The Bank of Nova ScotiaPacking Credit loans for the previous year comprised foreign currency packing credit loan that
were taken from Standard Chartered Bank, The Bank of Nova Scotia, BNP Paribas, ABN Amro
Bank and HSBC carrying interest rates of LIBOR plus 40 75 bps, repayable on expiry of 6
months from the date of drawdown and Rupee packing credit from State Bank of India carrying
interest rate of 5% per annum.
1.d: Schedule 13: Other Income and Schedule 16: Operating and other expenses
Table 9: Schedule 13 and 16: Operating Income and Operating & Other Expenses.
-
7/31/2019 Sandeep Fin
17/23
17
1:d Interpretation:
In Table 9 we can see that during financial year 2009-10 company has seen the profit of Rs.73
Million but in next financial year 2010-2011 they have seen the loss of 46 million.
3. Conclusion from Annual Statement 2010-2011:
DRL (Dr. Reddys Lab) has continuously used various sources of international funding and if we
talk about the ownership, foreign holing comprises 46.27% of total ownership. Initially they
were using GDR which they had converted into ADS and then again they converted those ADS
into equity shares. They have issued to ADR to their employees in subsidiary. They have taken
loan from various foreign financial institutions and banks like J.P Morgan, HSBC, ABN AMRO,
The Bank of Tokyo, and Mitsubishi UFJ LTD on LIBOR basis. They have also paid the loan
raised from European companies on EURIBOR.
They are aware of foreign currency fluctuations therefore they have created reserves like Foreign
currency translation reserve and Hedge Reserve. But last year they have seen the loss of
Rs.43Million because of the foreign currency fluctuations.
4. Analysis Based on Quarterly Results: Quarter 2, 2011-12
a) Effect of Depreciation in Rupee on Profits:
The convenience dollar rate for the quarter was at Rs. 49.05 per dollar, and the average dollar
rate for the quarter is at Rs. 45.80. As the Dollar rate was to volatile company had spent more on
Hedging. DRL has also seen Net forex gain of Rs. 151 mn ($3mn) versus net forex loss of
Rs.49mn ($1mn) in Q2 FY11. Till now they are getting benefit of this Rupee depreciation as
they got their major revenues from other countries and relatively their interest payment and other
foreign expenses are less.
b) Effect on Depreciation on Cash Flows:
Similarly their cash flows has also been improved by 22.58% with this depreciation.
-
7/31/2019 Sandeep Fin
18/23
18
Cash Flows in Lakhs (Rs):
30.9.2011 30.9.2010
7 5,961 6 1,966
5. News Track
Dr. Reddy's Lab inches up as ADR gains
Capital Market / 09:18 , Dec 26, 2011
Dr. Reddy's Laboratories rose 0.33% to Rs 1,595 at 9:17 IST on BSE after the company's American
depository receipt, or ADR gained 1.11% to settle at $30.01 on the New York Stock Exchange Friday, 23
December 2011.
Meanwhile, the BSE Sensex was up 63.13 points, or 0.4% to 15,801.83.
On BSE, 230 shares were traded in the counter as against an average daily volume of 33,606 shares in
the past one quarter.
The stock hit a high of Rs 1,619 and a low of Rs 1,595 so far during the day. The stock had hit a 52-week
high of Rs 1730.45 on 27 December 2010. The stock had hit a 52-week low of Rs 1387 at 22 August 2011.
The large-cap stock had outperformed the market over the past one month till 23 December 2011,gaining 3.88% compared with the Sensex's 0.25% rise. The scrip had also outperformed the market in
past one quarter, surging 7.02% as against 2.62% fall in the Sensex.
The company has equity capital of Rs 84.77 Crore. Face value per share is Rs 5.
On a consolidated basis, Dr. Reddy's Laboratories' net profit rose 7.3% to Rs 307.80 Crore on 21.2%
growth in net sales to Rs 2267.79 Crore in Q2 September 2011 over Q2 September 2010.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives.
http://www.indiainfoline.com/Markets/News/Dr-Reddys-Lab-inches-up-as-ADR-gains/4086759061
http://www.indiainfoline.com/Markets/News/Dr-Reddys-Lab-inches-up-as-ADR-gains/4086759061http://www.indiainfoline.com/Markets/News/Dr-Reddys-Lab-inches-up-as-ADR-gains/4086759061http://www.indiainfoline.com/Markets/News/Dr-Reddys-Lab-inches-up-as-ADR-gains/4086759061 -
7/31/2019 Sandeep Fin
19/23
19
Pharma firms to gain on depreciating rupee
Malini Bhupta / Mumbai December 20, 2011, 0:47 IST
Revenues and earnings to improve for companies with low forexliabilities and no forward cover.
The falling rupee is expected to benefit pharmaceutical companies in apositive way, claim analysts. The local currency has depreciated 18 percent over the last few weeks and this spells good news for domestic
pharmaceutical firms. Last year, the domestic pharma market grew at15.3 per cent, nearly three times the growth in developed markets, saysCentrums Ranjit Kapadia. While this growth is expected to continue
this year too, the falling rupee will add to it.
Analysts say, for several large players, half the total revenues come fromglobal markets. For these, the falling rupee will shore up earnings and
revenues. But, only those having no or low forex liabilities and forward covers will gain. Forinstance, 91 per cent revenues of Divi's Laboratories come from global sales, so the rupee fallwill impact these by an estimated 12 per cent in the second half of FY12 and seven per cent forthe full year. According to Emkay Global, the firm has not taken any forward covers and, as a
result, the rupee depreciation will have an estimated positive impact on Ebitda of 37 per cent inthe second half of FY12 and 21 per cent in FY12. Overall, the profit after tax (PAT) is expectedto increase 37 per cent in H2 and 21 per cent in FY12.
Like Divi's, there are several others that have a high share of global sales and low forexliabilities. Dr Reddy's, for instance, derives 80 per cent of its revenues from global sales, butthe firm has taken forward covers of $775 million and hedged its cash flows. As a result, theimpact on the EBITDA will be limited to 14 per cent in H2 and eight per cent for the full year.The company has foreign currency loans of $200 million. According to analysts, the overall PATis expected to increase 16 per cent in the second half of this year and nine per cent in FY12.Cipla is another player that will see some benefit flowing into its bottom line due to a weaker
rupee.
However, Glenmark is unlikely to benefit much from the rupee, though 72 per cent of itsrevenues come from global sales. Though the company has not taken any forward cover, it hasforeign currency loans of $350 million, which will result in raising total liabilities by Rs 155Crore in FY12. Despite this, PAT is expected to remain flat, claim analysts.
-
7/31/2019 Sandeep Fin
20/23
20
http://www.business-standard.com/india/news/pharma-firms-to-gaindepreciating-rupee/459047/
Pharmaceutical results preview for Q3FY12: Emkay
Published on Tue, Jan 10, 2012 at 18:34 | Source : Moneycontrol.com
Updated at Tue, Jan 10, 2012 at 19:08
Emkay Global Financial Services has come with its December quarterly earnings estimates forpharmaceutical sector. According to the research firm the sector is expected to report a growth of18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5%
of the overall growth.
Divi's Lab (+32%), Sun Pharma (+27%), Ipca Labs (+28%), Glenmark Pharma (+27%), Dr.Reddys (+23%) and Ranbaxy (+17%) will be outperformers. The laggards will be Uncihem Labs(+6%), Aurobindo (+6%) & GSK (+11%).
OPM for the Emkay Pharma Universe is expected to 24% compared to 22% in Q2FY12 and 21%in Q3FY11. Expansion in EBIDTA margins will 200-250bps on account of Rupee depreciationand 100-150bps due to Para-IVs.
EBITDA margin expansion will be led by Ranbaxy Labs (+1000bps YoY & +1389bps QoQ),Ipca Labs (+678bps YoY & +108bps QoQ), Sun Pharma (+1000bps YoY & -280bps QoQ) and
Dr. Reddys (+617bps YoY & 504bps QoQ).
PAT of Pharma universe is likely to grow by 51% YoY (25% QoQ) compared to 4% YoYgrowth in Q2FY12 driven by Rupee depreciation and Para-IVs
Growth in APAT will be on account of 69% growth in Sun Pharma, 77% growth in Dr. Reddys(led by Zyprexa), 420% growth in Ranbaxy (led by Lipitor) and 35% growth in Divi's Lab.
In the generics space -Ipca Labs and Glenmark Pharma are our preferred bet.
In the CRAMS space -Divi's and Jubilant Life are our preferred bet.
http://www.business-standard.com/india/news/pharma-firms-to-gaindepreciating-rupee/459047/http://www.business-standard.com/india/news/pharma-firms-to-gaindepreciating-rupee/459047/http://www.business-standard.com/india/news/pharma-firms-to-gaindepreciating-rupee/459047/ -
7/31/2019 Sandeep Fin
21/23
21
6. Ratio Analysis:
-
7/31/2019 Sandeep Fin
22/23
22
Debt Equity Ratio:
All these figures are in (Rs.) lakhs
Year/Qtr Qtr 2 2011 2010
Debt Equity Ratio Total Debt / Owners Fund 0.651049271 0.380940909
:Total Debt 313,031 172,359
: Owners Fund 480,810 452,456
DRL has increased the level of debt in the organization from .38 to .65 by raising loans and short
term borrowings. Earlier on 30.9.2010 their loans and short term borrowing were
Rs.121,214lakhs which is on 20.9.2011 is Rs.260,093lakhs.
-
7/31/2019 Sandeep Fin
23/23
23
A) Returns to Sale Qtr 2 2011 2010
Operating Profit Ratio Operating Profit / Net Sales *100 17% 17%
: Operating Profit = 37,445 32,266
: Net Sales = 226,779 187,037
Net Profit Ratio Net Profit / Net Sales *100 14% 15%
: Net Profit = 30,780 28,682
: Net Sales = 226,779 187,037
DRL second qtr 3-.9.2011 Net profit is increased by Rs.2098Lakhs but their net profit ratio is
declined by 1%. And in case of Operating profit their profit is increased by Rs.5179lakhs but
there is no change in their operating profit ratio.